Screener / SEC EDGAR /CIK 0001639691 /10-K filed Feb 25, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Devices

LivaNova PLC LIVN

LivaNova PLC is a market-leading global medical technology company. 10-K, Item 1

Employees
3,300
Headquarters
Gloucester
Next results
around Feb 24, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2024

Revenue of $1.3B through the costs to a net profit of $63.2M · income statement of the 10-K

10% operating margin
Revenue to Gross profit: $853.5MRevenue to Cost of revenue: $400.0MGross profit to Operating profit: $129.1MGross profit to Operating expenses: $724.4MOperating profit to Net profit: $63.2MOperating profit to Tax & other: $65.8MOperating expenses to R&D: $182.5MOperating expenses to Sales, admin & other: $541.9M Revenue: $1.3B REVENUE $1.3B +9% Y/Y Gross profit: $853.5M · 68% margin GROSS PROFIT $853.5M 68% margin · +13% Y/Y Cost of revenue: $400.0M · 32% of revenue COST OF REVENUE $400.0M 32% of revenue Operating profit: $129.1M · 10% margin OPERATING PROFIT $129.1M 10% margin Operating expenses: $724.4M · 58% of revenue OPERATING EXPENSES $724.4M 58% of revenue Net profit: $63.2M · 5% margin NET PROFIT $63.2M 5% margin · +260% Y/Y Tax & other: $65.8M · 5% of revenue TAX & OTHER $65.8M 5% of revenue R&D: $182.5M · 15% of revenue R&D $182.5M 15% of revenue Sales, admin & other: $541.9M · 43% of revenue SALES, ADMIN & OTHER $541.9M 43% of revenue
Gross profit $853.5M 68% margin · +13% Y/Y
Operating profit $129.1M 10% margin
Net profit $63.2M 5% margin · +260% Y/Y
The full income statement, year by year

LIVN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 10.7%, above 51% of 154 peers (their median 10.4%) REVENUE GROWTH 10.7% · above 51% Gross margin: 67.8%, above 60% of 107 peers (their median 63.4%) GROSS MARGIN 67.8% · above 60% Operating margin: 10.7%, above 54% of 138 peers (their median 9.8%) OPERATING MARGIN 10.7% · above 54% Net margin: 13.0%, above 66% of 153 peers (their median 6.7%) NET MARGIN 13.0% · above 66% FCF margin: 8.6%, above 44% of 144 peers (their median 10.1%) FCF MARGIN 8.6% · above 44%
LIVN Peer median Below the median

What changed

14 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 25, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Going concern language
    “In addition, future unanticipated large liability claims may raise substantial doubt about LivaNova’s ability to continue as a going concern.”
  • Receivables +11.8% ($193.2M to $216.0M) vs revenue +10.7% ($1.3B to $1.4B), +1.1 pts apart
9 more checks with nothing to note
  • Cash from operations $254.3M vs net income −$242.5M (FY ending Dec 31, 2025)
  • Inventory +11.6% ($147.6M to $164.7M) vs revenue +10.7% ($1.3B to $1.4B), +0.9 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Goodwill Impairment Assessment - Cardiopulmonary Reporting Unit
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

14 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 14 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Changes in global trade policies, including the imposition of tariffs, trade restrictions, export controls, sanctions, or other protectionist or retaliatory measures by the U.S. or other jurisdictions, may adversely affect LivaNova’s business, financial condition, and results of operations. Global trade conditions have become…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption could have a material adverse effect on LivaNova’s business, results of operations, financial condition and reputation.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time-consuming to develop and manufacture. The Company’s success depends on several factors, including its ability to appropriately allocate the Company’s R&D resources, integrate advanced software and AI capabilities,…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    AI technologies are increasingly being used across the global business landscape, including in the development of new or improved products and therapies in the medical technology industry. LivaNova has already employed certain AI technologies in its business in an attempt to enhance the Company’s products, technology, and therapies and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.0B$1.2B$1.3B$1.4B
Net income−$86.2M$17.5M$63.2M−$242.5M
Operating cash flow$69.9M$74.9M$183.0M$254.3M
Free cash flow$43.4M$39.9M$135.9M$173.3M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.4B ▲ 10.7% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

LivaNova PLC, Gloucester · from the 10-K filed Feb 25, 2026

LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.”

Headquarters
Gloucester
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
United Kingdom

Employees, at the top of the page: "As of December 31, 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LIVN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.